Top

Published in:

01-10-2012 | Original article

Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer

Published in: Strahlentherapie und Onkologie | Issue 10/2012

Abstract

Background

The goal of the current study was to investigate the tumor control probability (TCP) of advanced radiotherapy technologies for stage III non-small cell lung cancer (NSCLC) and to evaluate potential interplay effects between their applications.

Materials and methods

Three-dimensional conformal radiotherapy (3D-CRT) with conventionally fractionated doses of 66 Gy served as reference for 13 patients with stage III NSCLC. Isotoxic dose escalation relative to the corresponding 3D-CRT plans was performed for three technologies and their combinations: intensity-modulated radiotherapy (IMRT), IMRT with a simultaneous integrated boost (IMRT-SIB) of 10% to the gross tumor volume (GTV), and adaptive re-planning twice during the treatment course (ART). All analyses were based on accumulated dose distributions using deformable image registration of CT images, which were acquired weekly during the treatment course.

Results

IMRT reduced the mean lung dose (MLD) by 5.6% ± 3.8% compared to 3D-CRT. ART resulted in lung sparing of 7.9% ± 4.8% and 9.2% ± 3.9% in 3D-CRT and IMRT planning, respectively. IMRT and ART escalated the irradiation dose by 6.6% ± 3.2% and 8.8% ± 6.3%, respectively, which was not statistically different. For the 7 patients with the largest GTVs, IMRT-SIB was superior to IMRT and ART with dose escalation of 11.9% ± 3.7%. The combination of ART, IMRT, and SIB achieved maximum dose escalation in all 13 patients by 17.1% ± 5.4% on average, which increased TCP from 19.9% ± 7.0 to 37.1% ± 10.1%. Adaptive re-planning was required to continuously conform the escalated and hypofractionated SIB doses to the shrinking tumor.

Conclusion

Combining advanced radiotherapy technologies is considered as a safe and effective strategy to maximize local tumor control probability in stage III NSCLC.

Auperin A, Le Pechoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190PubMedCrossRef

Boda-Heggemann J, Lohr F, Wenz F et al (2011) kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 187:284–291PubMedCrossRef

Bortfeld T, Jokivarsi K, Goitein M et al (2002) Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol 47:2203–2220PubMedCrossRef

Brenner DJ (1993) Dose, volume, and tumor-control predictions in radiotherapy. Int J Radiat Oncol Biol Phys 26:171–179PubMedCrossRef

Chapet O, Thomas E, Kessler ML et al (2005) Esophagus sparing with IMRT in lung tumor irradiation: an EUD-based optimization technique. Int J Radiat Oncol Biol Phys 63:179–187PubMedCrossRef

Christian JA, Bedford JL, Webb S et al (2007) Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 67:735–741PubMedCrossRef

De Gersem WR, Derycke S, Colle CO et al (1999) Inhomogeneous target-dose distributions: a dimension more for optimization? Int J Radiat Oncol Biol Phys 44:461–468CrossRef

Feng M, Kong FM, Gross M et al (2009) Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 73:1228–1234PubMedCrossRef

Fenwick JD, Nahum AE, Malik ZI et al (2009) Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin Oncol (R Coll Radiol) 21:343–360

10.

Gillham C, Zips D, Ponisch F et al (2008) Additional PET/CT in week 5–6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol 88:335–341PubMedCrossRef

11.

Grills IS, Yan D, Martinez AA et al (2003) Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57:875–890PubMedCrossRef

12.

Grutters JP, Kessels AG, Pijls-Johannesma M et al (2010) Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 95:32–40PubMedCrossRef

13.

Guckenberger M, Baier K, Richter A et al (2009) Evolution of surface-based deformable image registration for adaptive radiotherapy of non-small cell lung cancer (NSCLC). Radiat Oncol 4:68PubMedCrossRef

14.

Guckenberger M, Krieger T, Richter A et al (2009) Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. Radiother Oncol 91:288–295PubMedCrossRef

15.

Guckenberger M, Richter A, Wilbert J et al (2011) Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int J Radiat Oncol Biol Phys 81:e275–e282PubMedCrossRef

16.

Guckenberger M, Richter A, Wilbert J et al (2011) Adaptive radiotherapy for locally advanced non-small cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. IJROBP 81:e275–282

17.

Guckenberger M, Wilbert J, Richter A et al (2011) Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 79:901–908PubMedCrossRef

18.

Kupelian PA, Ramsey C, Meeks SL et al (2005) Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys 63:1024–1028PubMedCrossRef

19.

Liao ZX, Komaki RR, Thames HD Jr et al (2010) Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76:775–781PubMedCrossRef

20.

Liu HH, Wang X, Dong L et al (2004) Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1268–1279PubMedCrossRef

21.

Martel MK, Ten Haken RK, Hazuka MB et al (1999) Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 24:31–37PubMedCrossRef

22.

Nakayama H, Satoh H, Kurishima K et al (2010) High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 78:645–650PubMedCrossRef

23.

Nguyen PL, Gu X, Lipsitz SR et al (2011) Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517–1524PubMedCrossRef

24.

Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28:5153–5159PubMedCrossRef

25.

Ramsey CR, Langen KM, Kupelian PA et al (2006) A technique for adaptive image-guided helical tomotherapy for lung cancer. Int J Radiat Oncol Biol Phys 64:1237–1244PubMedCrossRef

26.

Schwarz M, Alber M, Lebesque JV et al (2005) Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62:561–570PubMedCrossRef

27.

Sonke JJ, Lebesque Jvan Herk M (2008) Variability of four-dimensional computed tomography patient models. Int J Radiat Oncol Biol Phys 70:590–598PubMedCrossRef

28.

Tome WA, Fowler JF (2000) Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 48:593–599PubMedCrossRef

29.

Wurstbauer K, Weise H, Deutschmann H et al (2010) Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses >/= 80 Gy in standard fractionation. Strahlenther Onkol 186: 551–557PubMedCrossRef

Title: Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer
Publication date: 01-10-2012
Published in: Strahlentherapie und Onkologie / Issue 10/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0161-9

At a glance: The STEP trials

Springer Medicine

Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer

Abstract

Background

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2012

Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer

Angst und Depressivität bei Tumorpatienten im Verlauf der radioonkologischen Behandlung

Do clinicians and patients agree regarding symptoms?

Sind nichtkrebsdingte Todesursachen durch Suizid, kardiovaskuläre Erkrankung oder Pneumonie bei Patienten mit einem Karzinom der Mundhöhle oder Oropharynx vermeidbar?

Indikationen zur neoadjuvanten oder definitiven Radiochemotherapie beim Ösophaguskarzinom auf höchstem Evidenzniveau gesichert

Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity